XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide
access via the World Wide Web to its presentation at the Morgan Stanley
Global Healthcare Conference. The live presentation will occur at 8:10
a.m. Pacific Time (11:10 a.m. Eastern Time) on Wednesday, September 11,
2013. A replay of the presentation will also be available.
To access the live presentation via the Web, please go to www.XenoPort.com.
Please connect to the Website at least 15 minutes prior to the live
presentation to ensure adequate time for any software downloads that may
be necessary to listen to the Webcast.
A replay of the Webcast can be accessed for a minimum of one month and
will be available approximately 24 hours after the live presentation.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates
for the potential treatment of neurological disorders. XenoPort is
currently commercializing Horizant® (gabapentin enacarbil)
Extended-Release Tablets, its first approved product in the United
States, and developing a novel fumaric acid ester product candidate,
XP23829, as a potential treatment for relapsing-remitting multiple
sclerosis and/or psoriasis. Regnite® (gabapentin enacarbil)
Extended-Release Tablets is being marketed in Japan by Astellas Pharma
Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil.
XenoPort's pipeline of product candidates also includes potential
treatments for patients with spasticity related to spinal cord injury
and Parkinson's disease.
To learn more about XenoPort, please visit the Website at www.XenoPort.com.
Horizant, Regnite and XENOPORT are registered trademarks of
XenoPort, Inc.
XNPT2G
Copyright Business Wire 2013